NGNE - Neurogene Inc.

Insider Sale by Cvijic Christine Mikail (Pres, CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Cvijic Christine Mikail, serving as Pres, CFO at Neurogene Inc. (NGNE), sold 2,558 shares at $21.62 per share, for a total transaction value of $55,316.00. Following this transaction, Cvijic Christine Mikail now holds 103,240 shares of NGNE.

This sale represents a 2.00% decrease in Cvijic Christine Mikail's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, March 26, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 30, 2026, 4 days after the trade was made.

Neurogene Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Cvijic Christine Mikail

Cvijic Christine Mikail

Pres, CFO

Christine Mikail Cvijic is the President and Chief Financial Officer (CFO) of Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases.[[2]](https://www.investing.com/news/insider-trading-news/neurogene-president-buys-491400-in-company-stock-93CH-3741217)[[3]](https://whalewisdom.com/filing/cvijic-christine-mikail-4-2026-03-03-170353-0500-ngne) Based at Neurogene's office at 535 W 24th Street, 5th Floor, New York, NY 10011, she has demonstrated confidence in the company's future through significant insider purchases, including 24,000 shares acquired on November 22, 2024, at an average price of $20.475, increasing her holdings to 76,844 shares (some jointly owned with her spouse, David Cvijic).[[1]](https://www.quiverquant.com/news/Insider+Purchase:+President+and+CFO+of+$NGNE+(NGNE)+Buys+24,000+Shares)[[2]](https://www.investing.com/news/insider-trading-news/neurogene-president-buys-491400-in-company-stock-93CH-3741217)[[4]](https://www.gurufocus.com/insider/79753/christine-mikail-cvijic) More recent SEC filings show her ownership growing to approximately 105,798 shares as of early 2026, following routine tax-related share sales of 4,045 shares on March 13, 2026, to cover RSU vesting obligations, with additional unvested RSUs scheduled through 2029.[[3]](https://whalewisdom.com/filing/cvijic-christine-mikail-4-2026-03-03-170353-0500-ngne)[[5]](https://www.stocktitan.net/sec-filings/NGNE/form-4-neurogene-inc-insider-trading-activity-009892e0139f.html) Prior to Neurogene, Cvijic served as Chief Administrative Officer and General Counsel at Sio Gene Therapies Inc. (SIOX), highlighting her extensive experience in biotechnology administration, finance, and legal affairs.[[4]](https://www.gurufocus.com/insider/79753/christine-mikail-cvijic) Her career reflects a strong track record in gene therapy and biopharma sectors, with ongoing insider ownership valued at over $2 million in NGNE stock as of late 2024.[[4]](https://www.gurufocus.com/insider/79753/christine-mikail-cvijic)

View full insider profile →

Trade Price

$21.62

Quantity

2,558

Total Value

$55,316.00

Shares Owned

103,240

Trade Date

Thursday, March 26, 2026

10 days ago

SEC Filing Date

Monday, March 30, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Neurogene Inc.

Company Overview

No company information available
View news mentioning NGNE

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5228354

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime